In recent days, the world has watched with curiosity and growing alarm as scientists in the U.K. have described a newly identified variant of the coronavirus that appears to be more contagious than, and genetically distinct from, more established variants. Initial studies of the new variant prompted Prime Minister Boris Johnson to tighten restrictions over Christmas, and spurred officials in the Netherlands, Germany and other European countries to ban travel from the U.K.

Continue reading “The U.K. Coronavirus Variant: What We Know” →

The coronavirus vaccine made by Moderna moved closer to authorization on Thursday, a significant step that would expand the reach of the nation’s vaccination campaign to rural areas and many more hospitals.

As the nation buckled from uncontrolled spread of the disease, with 3,611 deaths on Wednesday setting yet another horrific record, a panel of independent experts recommended,by a vote of 20 in favor and one abstention, that the Food and Drug Administration authorize the Moderna vaccine for emergency use. The formal decision, expected on Friday, would clear the way for some 5.9 million doses to be shipped around the country starting this weekend.

Continue reading “F.D.A. Panel Endorses Moderna’s Covid-19 Vaccine” →

WASHINGTON — The coronavirus vaccine made by Moderna is highly protective, according to new data released on Tuesday, setting the stage for its emergency authorization this week by federal regulators and the start of its distribution across the country.

The Food and Drug Administration intends to authorize emergency use of the vaccine on Friday, people familiar with the agency’s plans said. The decision would give millions of Americans access to a second coronavirus vaccine beginning as early as Monday. The Pfizer-BioNTech vaccine, cleared last week, was the first to be authorized.

Continue reading “Moderna Vaccine Is Highly Protective Against Covid-19, the F.D.A. Finds” →

WASHINGTON — The coronavirus vaccine made by Pfizer and BioNTech provides strong protection against Covid-19 within about 10 days of the first dose, according to documents published on Tuesday by the Food and Drug Administration before a meeting of its vaccine advisory group.

The finding is one of several significant new results featured in the briefing materials, which include more than 100 pages of data analyses from the agency and from Pfizer. Last month, Pfizer and BioNTech announced that their two-dose vaccine had an efficacy rate of 95 percent after two doses administered three weeks apart. The new analyses show that the protection starts kicking in far earlier.

Continue reading “Pfizer’s Vaccine Offers Strong Protection After First Dose” →

Britain’s National Health Service began delivering shots of the Pfizer-BioNTech vaccine on Tuesday, opening a public health campaign with little precedent in modern medicine and making Britons the first people in the world to receive an authorized, fully tested vaccine.

Here’s a guide to some of the basics.

Should I be concerned about the safety of the vaccine in Britain?

Continue reading “U.K. Coronavirus Vaccine: Side Effects, Safety, and Who Gets It First” →